08:56:26 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-12-04 Årsstämma 2025
2024-11-05 Bokslutskommuniké 2024
2024-08-30 Kvartalsrapport 2024-Q3
2024-05-14 Kvartalsrapport 2024-Q2
2024-01-30 Kvartalsrapport 2024-Q1
2023-12-14 Ordinarie utdelning AMBU B 0.00 DKK
2023-12-13 Årsstämma 2024
2023-11-08 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q3
2023-05-03 Kvartalsrapport 2023-Q2
2023-02-07 Kvartalsrapport 2023-Q1
2022-12-15 Ordinarie utdelning AMBU B 0.00 DKK
2022-12-14 Årsstämma 2023
2022-11-15 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q3
2022-05-10 Kvartalsrapport 2022-Q2
2022-02-08 Kvartalsrapport 2022-Q1
2021-12-15 Ordinarie utdelning AMBU B 0.29 DKK
2021-12-14 Årsstämma 2022
2021-11-09 Bokslutskommuniké 2021
2021-08-17 Kvartalsrapport 2021-Q3
2021-05-12 Kvartalsrapport 2021-Q2
2021-01-27 Kvartalsrapport 2021-Q1
2020-12-10 Ordinarie utdelning AMBU B 0.29 DKK
2020-12-09 Årsstämma 2021
2020-11-11 Bokslutskommuniké 2020
2020-08-26 Kvartalsrapport 2020-Q3
2020-05-05 Kvartalsrapport 2020-Q2
2020-02-04 Kvartalsrapport 2020-Q1
2019-12-18 Ordinarie utdelning AMBU B 0.38 DKK
2019-12-17 Årsstämma 2020
2019-11-13 Bokslutskommuniké 2019
2019-08-22 Kvartalsrapport 2019-Q3
2019-05-01 Kvartalsrapport 2019-Q2
2019-01-31 Kvartalsrapport 2019-Q1
2018-12-13 Ordinarie utdelning AMBU B 0.40 DKK
2018-12-12 Årsstämma 2019
2018-11-13 Bokslutskommuniké 2018
2018-08-23 Kvartalsrapport 2018-Q3
2018-05-07 Kvartalsrapport 2018-Q2
2018-01-31 Kvartalsrapport 2018-Q1
2018-01-03 Split AMBU B 1:5
2017-12-14 Ordinarie utdelning AMBU B 1.85 DKK
2017-12-13 Årsstämma 2018
2017-09-30 Bokslutskommuniké 2017
2017-08-23 Kvartalsrapport 2017-Q3
2017-05-02 Kvartalsrapport 2017-Q2
2017-02-01 Kvartalsrapport 2017-Q1
2016-12-13 Ordinarie utdelning AMBU B 1.55 DKK
2016-12-12 Årsstämma 2017
2016-09-30 Bokslutskommuniké 2016
2016-08-19 Kvartalsrapport 2016-Q3
2016-05-03 Kvartalsrapport 2016-Q2
2016-01-29 Kvartalsrapport 2016-Q1
2015-12-11 Ordinarie utdelning AMBU B 0.95 DKK
2015-12-10 Årsstämma 2016
2015-11-11 Bokslutskommuniké 2015
2015-08-19 Kvartalsrapport 2015-Q3
2015-05-06 Kvartalsrapport 2015-Q2
2015-02-02 Kvartalsrapport 2015-Q1
2014-12-23 Split AMBU B 1:4
2014-12-18 Ordinarie utdelning AMBU B 3.75 DKK
2014-12-17 Årsstämma 2015
2014-11-13 Bokslutskommuniké 2014
2014-08-20 Kvartalsrapport 2014-Q3
2014-05-02 Kvartalsrapport 2014-Q2
2014-02-04 Kvartalsrapport 2014-Q1
2013-12-13 Ordinarie utdelning AMBU B 1.25 DKK
2013-12-12 Årsstämma 2014
2013-09-30 Bokslutskommuniké 2013
2013-08-20 Kvartalsrapport 2013-Q3
2013-05-02 Kvartalsrapport 2013-Q2
2013-02-05 Kvartalsrapport 2013-Q1
2012-12-14 Ordinarie utdelning AMBU B 3.00 DKK
2012-12-13 Årsstämma 2013
2012-09-30 Bokslutskommuniké 2012
2012-08-23 Kvartalsrapport 2012-Q3
2012-05-03 Kvartalsrapport 2012-Q2
2012-02-09 Kvartalsrapport 2012-Q1
2011-12-16 Ordinarie utdelning AMBU B 2.00 DKK
2011-12-15 Årsstämma 2012
2011-09-30 Bokslutskommuniké 2011
2011-08-25 Kvartalsrapport 2011-Q3
2011-05-09 Kvartalsrapport 2011-Q2
2011-02-07 Kvartalsrapport 2011-Q1
2010-12-17 Ordinarie utdelning AMBU B 2.50 DKK
2009-12-17 Ordinarie utdelning AMBU B 1.50 DKK
2005-03-01 Split AMBU B 1:2
2004-02-10 Split AMBU B 1:10

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Ambu är verksamma inom medicinteknik. Bolaget utvecklar och marknadsför diagnostisk utrustning för aktörer inom vård- och omsorg. Störst verksamhet återfinns inom utvecklingen av lösningar för anestesi, patientövervakning, diagnos samt utrustning för första hjälpen. Verksamhet innehas på global nivå med störst närvaro inom Europa och Nordamerika. Ambu grundades 1937 och har sitt huvudkontor i Ballerup.
2018-11-13 08:00:09

Ambu ends the year with 15% organic growth and an EBIT margin of 21.6%. Following a 2.5 percentage point EBIT margin increase, Ambu is on track to realising the targets of its 2020 strategy.


"We have now come to the end of the first year of our three-year strategy period, and we have created solid growth in our business. Our key figures and ratios are satisfactory, and we are positive about the future. In the coming years, we will launch new and innovative products and so help to address some of the challenges facing hospitals and healthcare professionals. Our focus - and the focus that drives Ambu every single day - is on contributing to making devices available to doctors and patients that are absolutely clean," says President & CEO Lars Marcher.

Highlights

Q4 2017/18

  • Organic growth of 15% (14%) was realised in Q4 in local currencies, based on revenue of DKK 729m (DKK 629m).  All three regions reported double-digit growth.
  • EBIT increased to DKK 165m (DKK 134m) with an EBIT margin of 22.6% (21.3%).

FY 2017/18

  • Revenue for the financial year was DKK 2,606m (DKK 2,355m) based on organic growth in local currencies of 15% (14%).  All three regions also reported double-digit growth for the full year.
  • EBIT was up 25% at DKK 563m (DKK 450m), with an EBIT margin of 21.6% (19.1%).
  • Total tax on profit for the year was recognised at 28% (23%).
  • Net profit for the year was up 12% at DKK 337m (DKK 301m).
  • The Board of Directors proposes that dividend of DKK 0.40 (DKK 0.37) be paid per share, corresponding to an increase of 8% and an unchanged pay-out ratio of 30%.
  • Net working capital at the end of the year was DKK 535m (DKK 457m), corresponding to 21% (19%) of revenue for the year.
  • Free cash flows totalled DKK 321m (DKK 321m), and gearing was 1.8 (1.4).
  • Ambu's Visualisation business continued the positive development, and in 2017/18 560,000 single-use endoscopes were sold against 364,000 last year, corresponding to a growth rate of 54% (82%).
  • The acquisition of Invendo Medical GmbH was closed on 25 October 2017 based on a cash payment of EUR 115m and an agreement on an additional payment of contingent consideration of up to EUR 110m, of which a sum of EUR 10m was paid following FDA approval of the colonoscope (SC210) in January 2018.

 Outlook 2018/19

 The management's outlook for 2018/19 is unchanged relative to the most recently announced outlook on 4 October 2018:

  • Organic growth in local currencies of approx. 15-16%
  • EBIT margin of approx. 22-24%
  • Free cash flows before acquisitions of approx. DKK 400-475m.

A conference call is being held today, 13 November 2018, at 11.00 (CET). Please call the following number five minutes before the start of the conference: +45 3544 5580. The conference can be followed via www.ambu.com/webcastQ42018 and is held in English. The presentation can be downloaded immediately before the conference call via the same link.

The company's annual general meeting will be held on 12 December 2018 at 13.00 at Hotel Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen, Denmark.


Contact
Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

Ambu A/S
Baltorpbakken 13
2750 Ballerup, Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com

Annual_Report_2017_18
Company_Announcement_no. 2 2018_19

--
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ambu A/S via Globenewswire